6505--Request for Infromation - U.S. Produced Pharmaceuticals

Form / Attachment / Pricing Sheet

This document is an Excel spreadsheet containing a list of pharmaceutical products, their specifications, and estimated annual requirements. It serves as a reference for potential bidders regarding the types and quantities of drugs the government anticipates procuring.

• Drug Name: Lists various injectable and oral medications.
• Strength & Vial/Package Size: Specifies the concentration and packaging of each drug.
• Estimated Annual Requirements: Provides an estimated quantity needed for each drug item.
• Requested Data: Includes columns for KSM Origin, API Origin, Packaging Material Origin, Final Drug Manufacturing Origin, and Manufacturer Name, indicating areas where origin information may be required from bidders.
• Can Supply?: A column for bidders to indicate their ability to supply the listed items.
• Comments: A field for additional notes.
• Definitions Sheet: Provides definitions for terms like KSM (Key Starting Materials), API (Active Pharmaceutical Ingredient), Other ingredients, and Packaging Material.

This product list is crucial for bidders to understand the specific pharmaceutical items and quantities relevant to the opportunity. It helps in assessing their capability to supply, preparing accurate pricing, and understanding potential origin requirements for raw materials, active ingredients, packaging, and final manufacturing. Bidders should review this list to determine which products they can offer and to gather information for their proposals.

Request for Information (RFI)

The Department of Veterans Affairs (VA) is conducting market research to identify sources of U.S. Produced Pharmaceuticals, pursuant to Executive Order (EO) 13944. The VA is seeking information to assess potential procurement opportunities that mitigate risks associated with global supply chain vulnerabilities for pharmaceuticals. The VA prioritizes pharmaceuticals fully qualifying as 'U.S.-Produced' but also values products with any U.S. manufacturing activity.

• U.S. Production Definition: Pharmaceuticals must meet the definition in EO 13944, requiring critical inputs and finished drug product manufacturing/processing within the United States.

• Product List: Pharmaceuticals of particular interest are detailed in Attachment 1.

• Origin of Components: Bidders must provide the country of origin for various ingredients and components to verify U.S. production status.

• Company Information: Details on company name, manufacturer name, and whether the bidder is the manufacturer or has a letter of commitment.

• National Drug Code (NDC): Offerors must provide a unique eleven-digit NDC, with the first five digits (labeler code) identifying the offeror.

• Pharmaceutical Prime Vendor (PPV) Agreements: Confirmation of existing business-to-business agreements with PPVs.

• Business Size: Identification as a Large or Small Business, with specific questions for small businesses regarding manufacturing percentage.

• Contract Length Preference: Information on desired contract length.

• Supply Capability: Ability to begin supplying products within 60 days of award, or an estimated timeframe.

• Response Date: June 24, 2026, 2:30 PM Central Time, Chicago, USA.

• Submission Method: Responses and completed spreadsheets should be emailed to Diana.Martinez1@va.gov, Teresa.Hussain@va.gov, and Nicholas.McGregor@va.gov.

• This RFI is for information and planning purposes only and does not constitute a solicitation.

• Responses are not offers and cannot form a binding contract.

• Responders are responsible for all associated expenses.

• Attachment 1 (VA Product List) is referenced.